- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Analysis of patient access to orphan drugs in Turkey ; volume:16 ; number:1 ; day:6 ; month:2 ; year:2021 ; pages:1-8 ; date:12.2021
Orphanet journal of rare diseases ; 16, Heft 1 (6.2.2021), 1-8, 12.2021
- Creator
-
Koçkaya, Güvenç
Atalay, Sibel
Oğuzhan, Gülpembe
Kurnaz, Mustafa
Ökçün, Selin
Sar Gedik, Çiğdem
Şaylan, Mete
Şencan, Nazlı
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-021-01718-3
- URN
-
urn:nbn:de:101:1-2021032919394463813180
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Koçkaya, Güvenç
- Atalay, Sibel
- Oğuzhan, Gülpembe
- Kurnaz, Mustafa
- Ökçün, Selin
- Sar Gedik, Çiğdem
- Şaylan, Mete
- Şencan, Nazlı
- SpringerLink (Online service)
Other Objects (12)
Patient access to orphan drugs in France
Mechanism of coordinated access to orphan drugs
Markenführung Orphan Drugs
Orphan drugs : Fortschritte für Patienten mit seltenen Krankheiten
Orphan drugs : Fortschritte für Patienten mit seltenen Krankheiten
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Predictors of orphan drug approval
Evidenz zu Orphan Drugs : Arbeitspapier
Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
Market access of orphan drugs and the role of multi-criteria decision making
Seltene Helden : Orphan Drugs in Deutschland
Comparing access to orphan medicinal products in Europe
Patient access to orphan drugs in France
Mechanism of coordinated access to orphan drugs
Markenführung Orphan Drugs
Orphan drugs : Fortschritte für Patienten mit seltenen Krankheiten
Orphan drugs : Fortschritte für Patienten mit seltenen Krankheiten
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Predictors of orphan drug approval
Evidenz zu Orphan Drugs : Arbeitspapier
Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
Market access of orphan drugs and the role of multi-criteria decision making
Seltene Helden : Orphan Drugs in Deutschland
Comparing access to orphan medicinal products in Europe
Patient access to orphan drugs in France
Mechanism of coordinated access to orphan drugs
Markenführung Orphan Drugs
Orphan drugs : Fortschritte für Patienten mit seltenen Krankheiten
Orphan drugs : Fortschritte für Patienten mit seltenen Krankheiten
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Predictors of orphan drug approval
Evidenz zu Orphan Drugs : Arbeitspapier
Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
Market access of orphan drugs and the role of multi-criteria decision making
Seltene Helden : Orphan Drugs in Deutschland